ALVAL Stock Overview
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||€6.16|
|52 Week High||€7.45|
|52 Week Low||€4.01|
|1 Month Change||7.32%|
|3 Month Change||-4.94%|
|1 Year Change||-12.00%|
|3 Year Change||70.64%|
|5 Year Change||-38.65%|
|Change since IPO||-38.40%|
Recent News & Updates
Is Valbiotis (EPA:ALVAL) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|ALVAL||FR Biotechs||FR Market|
Return vs Industry: ALVAL exceeded the French Biotechs industry which returned -39% over the past year.
Return vs Market: ALVAL exceeded the French Market which returned -14% over the past year.
|ALVAL Average Weekly Movement||6.3%|
|Biotechs Industry Average Movement||6.8%|
|Market Average Movement||5.0%|
|10% most volatile stocks in FR Market||9.1%|
|10% least volatile stocks in FR Market||2.9%|
Stable Share Price: ALVAL is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ALVAL's weekly volatility (6%) has been stable over the past year.
About the Company
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease.
Valbiotis Fundamentals Summary
|ALVAL fundamental statistics|
Is ALVAL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALVAL income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 30, 2022
|Earnings per share (EPS)||-0.89|
|Net Profit Margin||-2,913.09%|
How did ALVAL perform over the long term?See historical performance and comparison
Is ALVAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALVAL?
Other financial metrics that can be useful for relative valuation.
|What is ALVAL's n/a Ratio?|
Price to Book Ratio vs Peers
How does ALVAL's PB Ratio compare to its peers?
|ALVAL PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
Price-To-Book vs Peers: ALVAL is good value based on its Price-To-Book Ratio (4.2x) compared to the peer average (15.4x).
Price to Earnings Ratio vs Industry
How does ALVAL's PE Ratio compare vs other companies in the French Biotechs Industry?
Price-To-Book vs Industry: ALVAL is expensive based on its Price-To-Book Ratio (4.2x) compared to the French Biotechs industry average (2.6x)
Price to Book Ratio vs Fair Ratio
What is ALVAL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||4.2x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate ALVAL's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ALVAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ALVAL (€6.16) is trading below our estimate of fair value (€177.83)
Significantly Below Fair Value: ALVAL is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALVAL's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Valbiotis forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALVAL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).
Earnings vs Market: ALVAL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALVAL is expected to become profitable in the next 3 years.
Revenue vs Market: ALVAL's revenue (70.3% per year) is forecast to grow faster than the French market (5.9% per year).
High Growth Revenue: ALVAL's revenue (70.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALVAL's Return on Equity is forecast to be very high in 3 years time (83.2%).
Discover growth companies
How has Valbiotis performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALVAL is currently unprofitable.
Growing Profit Margin: ALVAL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALVAL is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare ALVAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALVAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).
Return on Equity
High ROE: ALVAL has a negative Return on Equity (-60.73%), as it is currently unprofitable.
Discover strong past performing companies
How is Valbiotis's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALVAL's short term assets (€25.2M) exceed its short term liabilities (€7.9M).
Long Term Liabilities: ALVAL's short term assets (€25.2M) exceed its long term liabilities (€6.3M).
Debt to Equity History and Analysis
Debt Level: ALVAL has more cash than its total debt.
Reducing Debt: ALVAL's debt to equity ratio has reduced from 162.2% to 39.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALVAL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALVAL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Valbiotis's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALVAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALVAL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALVAL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALVAL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALVAL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sébastien Peltier (43 yo)
Mr. Sébastien Peltier, Ph D., HDR serves as the Chief Executive Officer and Chairman of Valbiotis SA and is Co-Founder of Valbiotis. Mr. Peltier joined Laboratoire Lescuyer in 2007 and served as its in cha...
Experienced Management: ALVAL's management team is considered experienced (3.3 years average tenure).
Experienced Board: ALVAL's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Valbiotis SA's employee growth, exchange listings and data sources
- Name: Valbiotis SA
- Ticker: ALVAL
- Exchange: ENXTPA
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €59.874m
- Shares outstanding: 9.72m
- Website: https://www.valbiotis.com
Number of Employees
- Valbiotis SA
- rue Paul Vatine
- 12th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.